



This is a repository copy of *Effectiveness of the unified protocol for treating co-morbid health anxiety and depression : an empirical case study.*

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/174906/>

Version: Accepted Version

---

**Article:**

Gaskell, C., Hague, B. and Kellett, S. (2021) Effectiveness of the unified protocol for treating co-morbid health anxiety and depression : an empirical case study. *Behavioural and Cognitive Psychotherapy*. ISSN 1352-4658

<https://doi.org/10.1017/S1352465821000205>

---

© 2021 The Authors. This is an author produced version of a paper subsequently published in *Behavioural and Cognitive Psychotherapy*. Article available under the terms of the CC-BY-NC-ND license (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

### Abstract

**Aims:** The Unified Protocol (UP) is indicated when patients present with comorbidity, but no studies have investigated the effectiveness of the UP with comorbid health anxiety and depression. **Method:** An A/B single case design evaluated outcomes for a 27-year-old male presenting with health anxiety and comorbid depression. Following a 21-day assessment-baseline period, the manualised UP was delivered across a 42-day period containing seven intervention sessions. Four idiographic measures (occurrence and duration of health checking, sleep duration and food intake satisfaction) were collected daily throughout and two nomothetic measures were collected at four time-points. **Results:** All sessions were attended. Number of health checking episodes reduced from four per day to two per day. A 59 minute per day reduction in time spent health checking occurred and sleep increased by 100-minutes per night. There was little apparent change in terms of food intake satisfaction. There was a reliable and clinically significant reduction in depression. **Discussion:** Further testing of the effectiveness of the UP with comorbid health anxiety and depression in a true single case experimental design is now indicated.

## Introduction

Patients that present with comorbidity of anxiety and depression in routine practice present the cognitive behavioural therapist with a treatment selection dilemma (Barlow et al., 2004). One possible approach is to use a disorder specific cognitive behavioural therapy (CBT) treatment protocol, whilst monitoring concurrent improvements across other comorbidities. Another approach is to deliver one protocol, evaluate outcome, and then begin another protocol. Criticisms of the staged approach is that is time consuming, creates potential confusion for the patient and requires the therapist to be ‘pan-protocol competent’ (see McManus et al., 2010 for a review). An alternative approach is to take a more parsimonious approach and deliver a transdiagnostic treatment protocol (Wilamowska et al., 2010). Indeed, two meta-analyses have demonstrated the efficacy of transdiagnostic CBT in treating anxiety and depression (Andersen et al., 2016; McEvoy et al., 2009).

The unified protocol (UP; Barlow et al., 2010) is a transdiagnostic and manualised form of CBT developed for the treatment of comorbid anxiety and mood disorders. The UP targets the shared mechanisms of depression and anxiety (Hirschfeld, 2001) using a short-term, focused, structured and manualised treatment approach. Farchione et al., (2012) compared 18-sessions of the UP with a waitlist control to show that the UP facilitated significant differential improvement in severity, affect and symptom interference. Barlow et al., (2017) found that 16-sessions of the UP was as effective as single-disorder protocols, but had lower rates of treatment attrition. Both of these clinical trials however had very limited representation of health anxiety as either the principal or comorbid disorder. This lack of evidence for the effectiveness of the UP in treating health anxiety as a primary concern has been attributed to overlap of health anxiety symptomology with OCD and panic disorder, leading to potential misclassification (Olatunji et al., 2014). One pilot randomised control trial set in Iran (Mohammadpour et al., 2018) has also investigated the effectiveness of

pharmacotherapy with and without the addition of 12-sessions of the UP for patients with a primary diagnosis of generalised anxiety disorder (GAD). Patients showed a significant reduction in a variety of outcomes, including health anxiety, but it is not currently clear the degree to which findings would generalise to routine care settings in other countries.

Collectively, these findings provide limited support for the UP in treating health anxiety where it is the principal or comorbid disorder. Strong support has been shown for single-disorder protocol CBT in the treatment of health anxiety (see Olatunji et al., 2014 for a meta-analysis). So, initial practice-based evidence is required to determine if the UP is effective for patients presenting with health anxiety as a primary concern to support the rationale for any future randomised clinical trials (RCT) of the UP for health anxiety. An efficient way of generating such practice-based effectiveness evidence is via single case methods. The single case experimental design (SCED) method is based on the establishment of a baseline, and thereafter treatment is introduced and/or removed (sometimes randomly) according to the specified methodology (Morley, 2017). A wide range of SCED methodologies are possible to evaluate the effectiveness of CBT in routine practice, including alternating treatment designs (e.g. Kellett et al., 2020) and multiple-baseline designs (e.g. Sauer-Zavala et al., 2017).

Where only a basic bi-phasic A/B single case design is implemented, then this not a SCED but rather an empirical case-study, as no aspect or component of the intervention is experimentally controlled (Shadish & Sullivan, 2011). A bi-phasic design is still nevertheless advantageous in the accrual of initial practice-based evidence because such designs are easy to implement, create few ethical dilemmas and usefully integrate idiographic and nomothetic outcome measurement (McMillan & Morley, 2010). Arco (2015) for example used an empirical case study design to assess the effectiveness of CBT and pharmacotherapy for OCD and comorbid depression. More recently a number of empirical case studies and SCEDs

evaluating UP effectiveness have been completed (Boswell et al., 2014; Hague et al., 2015; Sauer-Zavala et al., 2017). Hague et al (2015) for example, used an A/B bi-phasic design to evaluate the effectiveness of 8-sessions of the UP with an older adult experiencing co-morbid anxiety and depression.

This study used an A/B empirical case study to evaluate the clinical effectiveness of the UP in a case of health anxiety and co-morbid depression in a working age adult. The study had three aims. Firstly, to understand the feasibility of delivering brief UP in routine practice in terms of treatment engagement and attendance. Secondly, to test whether the UP was effective in treating target idiographic measures (i.e., reduce the cumulative time spent health checking, reduce number of health checking episodes, create a more stable sleep pattern, and greater satisfaction with food intake). Thirdly, to assess reliable and clinically significant change on the nomothetic measures of checking behaviour, depression and general psychological distress.

## **Method**

### **Participant and Setting**

Consent was sought from the patient to complete and report the study. The UP was delivered by a trainee clinical psychologist working under the close supervision of a BABCP accredited principle clinical psychologist. The male patient ('James'; name changed to protect anonymity) was 27-years old. He was referred to a community team in a secondary care mental health service from his General Practitioner. Throughout the study, the patient was prescribed Fluoxetine for depression and Buspirone for anxiety. The patient had a long history of anxiety and depression, including a hospital admission for attempted suicide (9-years previously) and regular periods of crisis contact with mental health services. Since leaving school, due to his poor mental health, he had only been able to sustain brief periods

of employment. James would rarely leave the house (i.e. due to low mood/motivation and fear of embarrassment about people judging his checking behaviours). Onset of health checking occurred when he was 13-years of age. The most frequent form of checking was for potential throat cancer, which deterred eating, and also created a poor sleep cycle through constant health checking at night. James stated that his mood was typically depressed, and that the onset of his depression was 15-years of age. His primary concern was being chronically fearful about his physical health status as he frequently believed that he had some form of undiagnosed serious illness, typically cancer. His uncle had died of cancer when he was an adolescent, triggering for James a psychological focus on his health. James reported occasional health-related panic attacks and frequent reassurance seeking behaviour towards his mum and GP. He had previously received formal diagnoses of OCD, depression, panic disorder, health anxiety and dependent personality traits. James had 16-sessions of CBT 2-years previously for GAD in the Improving Access to Psychological Therapies (IAPT) service using the Dugas treatment protocol for GAD (Dugas et al., 1998) which had been unsuccessful.

### **Idiographic Measures; Description, Timing and Analysis**

Four idiographic measures were co-developed with James: cumulative time spent health checking (recorded as time elapsed in minutes), number of daily health checking episodes (count of checking episodes lasting longer than 30 seconds), sleep duration the previous night (recorded in hours and minutes) and food intake satisfaction (5-point Likert scale from 'most satisfied' to 'least satisfied'). James was encouraged to record checking behaviour live during the day and following each checking episode. Eating satisfaction was recorded at the end of each day and sleep duration was recorded the following morning.

Baseline phases were assessed for stability through visual analysis (time-series plots with ordinary least squares regression lines) and statistical analysis (Kendall's  $\tau$ ). Should any idiographic measure demonstrate statistically significant baseline trend then adjustments would be made using  $\tau^U$  (Parker et al., 2011). Three tests of non-overlap were employed to assess intervention effectiveness. Percentage of data exceeding the median (PEM) refers to the percentage of intervention phase data that exceeds the median of the baseline phase. Nonoverlap of all pairs (NAP; Parker & Vannest, 2009) makes use of all data, comparing every baseline point to every intervention point. Percentage of all nonoverlapping data (PAND) is the smallest percentage of data points that would need to be removed to ensure no overlap between phases. The Scruggs and Mastropiere (1998) criteria for categorising nonoverlap effect sizes were used (50-69% = 'questionable effectiveness', 70-89% = 'moderate effectiveness', 90%+ = 'highly effective'). To assess variability of idiographic measures, visual analysis of scatterplots and changes in the standard deviation (SDs) between phases were considered. Differences in phase level was assessed using  $\tau^{A-B}$  for which the p-value equates to that produced by a Mann-Whitney test (Parker et al., 2011).

### **Nomothetic Measures; Description, Timing and Analysis**

Nomothetic measures were collected at four time points; (1) baseline start, (2) intervention start, (2) mid-intervention and (4) intervention end. The two valid and reliable nomothetic measures used were the CORE-10 (Barkham et al., 2013) and the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS; Goodman et al., 1989). The CORE-10 is a ten-item measure of global psychological distress selected because of the need to evaluate the impact of the CBT on the general psychological well-being of the patient. The Y-BOCS is a ten-item measure of checking behaviour and intrusions. The Y-BOCS was selected because the patient experienced anxiety-provoking intrusions about his health and engaged in health

checking compulsive behaviours. To assess change on these measures, reliable and clinically significant change indices (RCSI) were used (Jacobson & Truax, 1991). To achieve RCSI there would be reductions in Y-BOCS and CORE-10 scores (from intervention-start to intervention-end) that both (a) meet the reliable change index (RCI) and (b) shift into the non-clinical range. The CORE-10 has a RCI of 6 and clinical cut-offs of 13 for depression and 11 for general psychological distress. The Y-BOCS has a clinical cut-off of 13 and an RCI of 5.

### **Design**

An A/B design comprising a 21-day baseline phase and 42-day intervention phase. The idiographic measures were therefore collected on a daily basis across the two phases, totalling an  $N = 63$ -day study timeline.

### **Baseline Procedure**

Table 1 details the content of the assessment and treatment sessions. The baseline phase contained three assessment sessions (sessions 1-3). The initial assessment appointment allowed for setting up of the diary (idiographic measures). Idiographic measures were collaboratively designed to reflect the main concerns of the patient and which he brought to each session for review. The UP formulation was built collaboratively towards the end of the third and final assessment appointment. Intervention strategies were not employed until the first treatment session (session four). The formulation included the main schematic features of the UP (Barlow et al., 2017). In response to arising symptoms of health anxiety and comorbid depression, James would employ a range of emotionally-driven behaviours (i.e. persistent checking, reassurance seeking, withdrawal and rumination). These behaviours would frequently lead to undesired consequences (i.e. reduced energy, poor sleep cycle,



isolation and dependency), thus perpetuating distress. The aim of the UP was to provide James with alternative, flexible and more adaptive means of responding to his emotional distress.

### **Intervention Procedure**

The UP was employed across seven treatment sessions (i.e., sessions 4-10) with the eight modules being covered sequentially in the treatment phase. The first two modules were combined during the first treatment session, whilst remaining modules received one session each. The contract of therapist input was 10-sessions (including assessment) due to the time limits of the clinical placement. The rationale for delivering the UP protocol was because the patient's treatment in IAPT (i.e. using a disorder specific approach) had been unsuccessful. Therefore, an alternative, transdiagnostic approach was selected. A cognitive-behavioural approach was still considered appropriate, based on the concerns of the patient and also awareness of the UP evidence base. Sessions lasted for 50-minutes and were delivered in an out-patient community clinic. Homework was agreed at the termination of each session and reviewed at the subsequent session.

### **Results**

All sessions were attended and homework was consistently completed, demonstrating treatment acceptability. Figure 1 contains time-series plots for the four idiographic measures with fitted baseline median and ordinary least squares trend lines. There was limited baseline trend shown visually through OLS trend lines. This was confirmed by statistical analysis (Kendall's  $\tau$ , Table 2) as there was no significant baseline trend for any of the idiographic measure baseline phases. Baseline trend adjustment was therefore not indicated for other analyses.

For checking episodes, a highly variable baseline was shown ( $M = 4.00$ ,  $SD = 2.59$ ). During the treatment phase there was a reduction shown in both level (to  $M = 1.67$ ) and variability ( $SD = 1.24$ ). Similar findings were shown for the checking time measure. That is, there was a highly variable baseline phase ( $M = 83.10$ ,  $SD = 102.65$  [minutes]) followed by reductions in level (to  $M = 24.24$ ) and variability (to  $SD = 31.70$ ). For both of these measures, significant differences between phases were shown using  $\tau^{A-B}$ . Practically, a significant reduction was shown in the number of minutes spent health checking each day (i.e., 59-minute reduction). There was also a significant reduction in the number of checking episodes per day (i.e. four during baseline, two during treatment). The nonoverlap effect-sizes (Table 2) for checking measures showed a moderate to highly effective intervention.

For sleep, there was a highly variable baseline phase ( $M = 7.71$ ,  $SD = 3.98$ ). An increase in level ( $M = 9.24$ ) was shown during the intervention phase, but this was not significant. Nonoverlap results indicated questionable to moderate effect-sizes for increases in sleep duration due to intervention. Changes in sleep stability showed marked improvement (to  $SD = 2.09$ ). For food intake (satisfaction with) there was a minor increase in mean from the baseline phase ( $M = 3.38$ ) to the intervention phase ( $M = 3.62$ ) although not significant. This was accompanied by only questionable effect-sizes.

Table 3 reports the nomothetic outcomes. The CORE-10 shifted from ‘moderate distress’ to ‘low distress’ and met RCSI for depression and general psychological distress. The Y-BOCS had a 9-point reduction from ‘severe’ to ‘mild’ but remained two points above the clinical cut-off at end of treatment.

## Discussion

This study was the first single case approach to investigate the effectiveness of abbreviated UP treatment for comorbid health anxiety and depression in a working age adult.

Improvements were shown for time spent checking per day and number of daily checking episodes. Such improvements are noticeable given the limited time in treatment (i.e., 7 treatment sessions). Improvements were less evident for satisfaction with food intake, although this may have been hindered by the relatively less severe baseline phase. Sleep was more stable according to changes in standard deviations; however, there was not a significant increase in sleep duration. Reliable and clinically significant change was shown for general psychological distress and depression. Improvement was also shown for checking symptoms (Y-BOCS), but this only constituted reliable change. With regards to how the effects of the intervention were generalised, the patient reported engaging in more regular social activity with his friends and family and that he had started to investigate attending University courses. These results combined support the partial effectiveness of abbreviated UP when treating health anxiety and depression. These findings also provide further support for the UP in delivering changes on idiographic outcomes. A strength of this study was the utilisation of the non-parametric statistics to supplement visual analysis (Chen et al., 2016) and the absence of statistically significant trend in the baseline period.

All sessions were attended, and homework completion was consistent. This provides additional support to the emerging evidence base for the acceptability of individualised transdiagnostic approaches (Sauer-Zavala et al., 2016; Sauer-Zavala et al., 2017). The module selection and ordering in this study was not personalised to the patient or presenting problem. Modules were delivered in relatively equal amounts. Future SCEDs should attempt to test the effectiveness of idiosyncratic UP formulations and the tailoring of module ordering and dosage. This is because support has previously been shown for individualising UP module ordering (Sauer-Zavala et al., 2017). For example, in the current case, more time being devoted to the mechanisms thought to underpin health anxiety (e.g., the role of interoceptive conditioning) may have led to greater improvements. Future investigation of dose-response

relationship in the UP for health anxiety is also required. This is because disorder-specific CBT protocols recommend longer treatment phases (e.g. Salkovskis & Kirk, 1989) and also in light of the apparent dose-response relationship for CBT and health anxiety improvements (Olatunji et al., 2014).

The justification for just 10 sessions of input was purely based on the time limitations of the clinical placement and so it is acknowledged that this treatment was shorter than required for full UP treatment (16 sessions, Barlow et al., 2017). This shorter course of treatment may have curtailed the effectiveness of the intervention. Despite the limited number of sessions, gains were made, particularly with regards to reduced health checking. Checking behaviour as measured with the Y-BOCS showed reliable but not clinically significant change. This might have occurred with an extended intervention phase and/or emphasising and concentrating on the modules suspected as most relevant to checking behaviour (e.g., interoceptive exposure). A further consideration is whether the choice to conceptualise the primary presenting problem as health anxiety was the most appropriate. Given the patient's comorbidity (i.e., with depression) and overlapping symptomology (i.e., checking is also a feature of OCD), it is reasonable to consider that a different clinician may have provided an alternative clinical formulation or treatment, and this may have been more effective.

Critics could question whether the UP was delivered at all or in sufficient depth due to the limited number of sessions. An issue with this study is also that therapist input occurred during the baseline phase. The UP was not a focus in these early baseline sessions; however, the UP formulation was developed towards the end of the final assessment session. Receiving this formulation may have led to a level of improvement between the final assessment session and the first treatment session. Despite this, the visual trends of improvement within baseline periods (for three of the idiographic measures) were not statistically significant. Other

methodological limitations were the lack of diagnostic certainty, lack of a genuine experimental design, lack of idiographic measures of health obsessions, mood or reassurance-seeking, lack of any formal treatment adherence checks, lack of clinical competency checks, the lack of a nomothetic measure specific to health anxiety, lack of nomothetic generalisability measures and lack of any follow-up.

These acknowledged limitations allow the following recommendations for future single-case investigations using the UP; (a) use of adherence, fidelity and competency checks, (b) ensuring spread of idiographic measures across anxiety and depression, (c) inclusion of control idiographic measures, (d) inclusion of generalisation nomothetic measures, (d) inclusion of a cross-over treatment comparison phase, or a withdrawal phase, (e) inclusions of a follow-up phase, (f) gathering of informant idiographic outcomes to assess changes in reassurance-seeking and (g) the employment of diagnostic procedures (e.g. Anxiety Disorder Interview Schedule; ADIS-IV-L; Di Nardo et al., 1994).

In conclusion, this is the first empirical case study to investigate the effectiveness of abbreviated UP in treating health anxiety and comorbid depression in a working age adult. Encouraging results have been found for the relatively brief intervention used. This research should act as a stimulus for therapists in routine practice to use the UP and evaluate outcomes using single case quasi-experimental and ethically appropriate true-experimental methods. This research showed improvements in behaviourally based idiographic measures and so exploring cognitive outcomes would be a useful next avenue. As the UP acts on the shared mechanisms of depression and anxiety and because comorbidity is so frequent in Primary Care settings, then the UP appears a valuable tool for IAPT CBT therapists. A pilot trial of the UP versus any single-disorder protocol is now indicated in IAPT settings and IAPT CBT therapists are also encouraged to produce genuine SCEDs of the UP.

## References

- Andersen, P., Toner, P., Bland, M., & McMillan, D. (2016).** Effectiveness of transdiagnostic cognitive behaviour therapy for anxiety and depression in adults: A systematic review and meta-analysis. *Behavioural and Cognitive Psychotherapy*, *44*(6), 673-690. <https://doi.org/10.1017/S1352465816000229>
- Arco, L. (2015).** A case study in treating chronic comorbid obsessive-compulsive disorder and depression with behavioral activation and pharmacotherapy. *Psychotherapy*, *52*(2), 278-286. <https://doi.org/10.1037/pst0000018>
- Barkham, M., Bewick, B., Mullin, T., Gilbody, S., Connell, J., Cahill, J., Mello-Clark, J., Richards, D., Unsworth, G., & Evans, C. (2013).** The CORE-10: A short measure of psychological distress for routine use in the psychological therapies. *Counselling and Psychotherapy Research*, *13*(1), 3-13.  
<https://doi.org/10.1080/14733145.2012.729069>.
- Barlow, D. H., Allen, L. B., & Choates, M. L. (2004).** Toward a unified treatment for emotional disorders: History of development. *Behavior Therapy*, *35*(2), 205-230. doi: 10.1016/j.beth.2016.11.005. [https://doi.org/10.1016/S0005-7894\(04\)80036-4](https://doi.org/10.1016/S0005-7894(04)80036-4)
- Barlow, D. H., Farchione, T. J., Bullis, J. R., Gallagher, M. W., Murray-Latin, H., Sauer-Zavala, S., Bentley, K. H., Thompson-Hollands, J., Conklin, L. R., Boswell, J. F., Ametaj, A., Carl, J. R., Boettcher, H. T., & Classiello-Robbins, C. (2017).** The unified protocol for transdiagnostic treatment of emotional disorders compared with diagnosis-specific protocols for anxiety disorders: A randomized clinical trial. *JAMA Psychiatry*, *74*(9), 875-874.  
<https://doi.org/10.1001/jamapsychiatry.2017.2164>

- Barlow, D. H., Farchione, T. J., Fairholme, C. P., Ellard, K. K., Boisseau, C. L., Allen, L. B., & Ehrenreich-May, J. (2010).** *Unified Protocol for transdiagnostic treatment of emotional disorders*. Oxford University Press.
- Boswell, J. F., Anderson, L. M., & Barlow, D. H. (2014).** An idiographic analysis of change processes in the unified transdiagnostic treatment of depression. *Journal of Consulting and Clinical Psychology, 82(6)*, 1060–71.  
<http://dx.doi.org/10.1037/a0037403>
- Chen, M., Hyppa-Martin, J. K., Reichle, J. E., & Symons, F. J. (2016).** Comparing single case design overlap-based effect size metrics from studies examining speech generating device interventions. *American Journal on Intellectual and Developmental Disability, 121(3)*, 169–193. <https://doi.org/10.1352/1944-7558-121.3.169>
- Connell, J., & Barkham, M. (2007).** CORE-10 User Manual, Version 1.1. CORE System Trust & CORE Information Management Systems Ltd.
- Deacon, B. J., & Abramowitz, J. Z. (2005).** The Yale-Brown Obsessive Compulsive Scale: factor analysis, construct validity, and suggestions for refinement. *Journal of Anxiety Disorders, 19(5)*, 573–585. <https://doi.org/10.1016/j.janxdis.2004.04.009>
- Di Nardo, P. A., Brown, T. A., & Barlow, D. H. (1994).** *Anxiety Disorders Interview Schedule for DSM-IV: Lifetime version (ADIS-IV-L)*. Psychological Corporation.
- Dugas, M. J., Gagnon, F., Ladouceur, R., Freeston, M. H. (1998).** Generalized anxiety disorder: A preliminary test of a conceptual model. *Behaviour Research and Therapy, 36(2)*, 215-226. [https://doi.org/10.1016/S0005-7967\(97\)00070-3](https://doi.org/10.1016/S0005-7967(97)00070-3)
- Farchione, T. J., Fairholme, C. P., Ellard, K. K., Boisseau, C. L., Thompson-Hollands, J., Carl, J. R., Gallagher, M. W., & Barlow, D. H. (2012).** Unified protocol for

transdiagnostic treatment of emotional disorders: a randomized controlled trial.

*Behavior Therapy*, 43(3), 666-678. <https://doi.org/10.1016/j.beth.2012.01.001>

**Frost, R. O., Steketee, G., Krause, M. S., & Trepanier, K. L.** (1995). The relationship of the Yale-Brown obsessive compulsive scale (YBOCS) to other measures of obsessive compulsive symptoms in a nonclinical population. *Journal of Personality Assessment*, 65(1), 158-168. [https://doi.org/10.1207/s15327752jpa6501\\_12](https://doi.org/10.1207/s15327752jpa6501_12)

**Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., Heninger, G. R., & Charney, D. S.** (1989). The Yale-Brown Obsessive Compulsive Scale: i. Development, use and reliability. *Archives of General Psychiatry*, 46(11), 1006-1011.  
<https://doi.org/10.1001/archpsyc.1989.01810110048007>

**Hague, B., Scott, S., & Kellett, S.** (2015). Transdiagnostic CBT treatment of co-morbid anxiety and depression in an older adult: Single case experimental design. *Behavioural and Cognitive Psychotherapy*, 43(1), 119-124.  
<https://doi.org/10.1017/S1352465814000411>

**Hirschfeld, R. M.** (2001). The comorbidity of major depression and anxiety disorders: Recognition and management in primary care. *Journal of Clinical Psychiatry*, 3(6), 244-254. <https://doi.org/10.4088/pcc.v03n0609>

**Jacobson, N., & Truax, P.** (1991). Clinical significance: A statistical approach to defining change in psychotherapy research. *Journal of Consulting and Clinical Psychology*, 59(1), 12-19. <http://doi.org/10.1037/0022-006X.59.1.12>

**Kellett, S., Oxborough, P., & Gaskell, C.** (2020). Treatment of compulsive buying disorder: Comparing the effectiveness of cognitive behavioural therapy with person-centred



experiential counselling. *Behavioural and Cognitive Psychotherapy*. <http://doi.org/10.1017/S1352465820000521>

**McEvoy, P. M., Nathan, P., & Norton, P. J.** (2009). Efficacy of transdiagnostic treatments:

A review of published outcome studies and future research directions. *Journal of Cognitive Psychotherapy*, *23*(1), 20-33. <http://doi.org/10.1891/0889-8391.23.1.20>

**McManus, F., Shafran, R., & Cooper, Z.** (2010). What does a ‘transdiagnostic’ approach

have to offer the treatment of anxiety disorders? *British Journal of Clinical Psychology*, *49*(4), 491-505. <https://doi.org/10.1348/014466509X476567>

**McMillan, D., & Morley, S.** (2010). Single case quantitative methods for practice based

evidence. In M. Barkham, G. E. Hardy, & J. Mellor-Clark (Eds.), *Developing and Delivering Practice Based Evidence: A guide for the psychological therapies* (pp. 109-138). Wiley-Blackwell.

**Mohammadpour, M., Sadeghi, K., Foroughi, A., Amiri, S., Parvizifard, A., &**

**Khoramniya, S.** (2018). The unified protocol for transdiagnostic treatment of emotional disorders: Treatment of comorbid psychopathology accompanying a generalized anxiety disorder. *International Journal of Behavioral Science*, *12*(3), 125-131.

**Morley, S.** (2017). *Single-case methods in clinical psychology: A practical guide*. Routledge.

**Olatunji, B. O., Kauffman, B. Y., Meltzer, S., Davis, M. L., Smits, J. A., & Powers, M.**

**B.** (2014). Cognitive-behavioral therapy for hypochondriasis/health anxiety: A meta-analysis of treatment outcome and moderators. *Behaviour Research and Therapy*, *58*, 65-74. <https://doi.org/10.1016/j.brat.2014.05.002>

**Parker, R. I., & Vannest, K. J.** (2009). An improved effect size for single-case research:

Nonoverlap of all pairs. *Behavior Therapy*, *40*(4), 357-367.

<http://doi.org/10.1016/j.beth.2008.10.006>

**Parker, R. I., Vannest, K. J., & Davis, J. L.** (2011). Effect size in single-case research: A

review of nine nonoverlap techniques. *Behavior Modification*, *35*(4), 303-322.

<https://doi.org/10.1177/0145445511399147>

**Salkovskis, P. M., & Kirk, J.** (1989). Obsessional disorders. In K. Hawton, P. M.

Salkovskis, J. Kirk, & D. M. Clark (Eds.), *Cognitive behavioural therapy for*

*psychiatric problems: A practical guide* (pp. 129-168). Oxford University Press.

**Sauer-Zavala, S., Bentley, K. H., & Wilner, J. G.** (2016). Transdiagnostic treatment of

borderline personality disorder: A clinical replication series. *Journal of Personality*

*Disorders*, *30*(1), 35-51. [https://doi.org/10.1521/pedi\\_2015\\_29\\_179](https://doi.org/10.1521/pedi_2015_29_179)

**Sauer-Zavala, S., Cassiello-Robbins, C., Conklin, L. R., Bullis, J. R., Thompson-**

**Hollands, J., & Kennedy, K. A.** (2017). Isolating the unique effects of the unified

protocol treatment modules using single case experimental design. *Behavior*

*Modification*, *41*(2), 286-307. <https://doi.org/10.1177/0145445516673827>

**Scruggs, T. E., & Mastropiere, M. A.** (1998). Summarizing single-subject research: Issues

and applications. *Behavior Modification*, *22*(3), 221-242.

<https://doi.org/10.1177/01454455980223001>

**Shadish, W. R., & Sullivan, K. J.** (2011). Characteristics of single-case designs used to

assess intervention effects in 2008. *Behaviour Research Methods*, *43*(4), 971-980.

<https://doi.org/10.3758/s13428-011-0111-y>

**Wilamowska, Z. A., Thompson-Hollands, J., Fairholme, C. P., Ellard, K. K., Farchione, T. J., & Barlow, D. (2010).** Conceptual background, development, and preliminary data from the unified protocol for transdiagnostic treatment of emotional disorders. *Depression and Anxiety, 27(10)*, 882-890. <https://doi.org/10.1002/da.20735>

Table 1: treatment content and UP adherence information

Session (phase)	UP module and content	Homework
One (A)	Introductory assessment appointment and design of idiographic measure.	Diary keeping
Two (A)	Shortened appointment due to patient illness/fatigue. Assessment continued.	Diary keeping
Three (A)	Completion of assessment period. Development of shared case formulation.	Diary keeping
Four (B)	<b>Module 1+2</b> (motivation enhancement + psychoeducation): Explanation of treatment rationale, education on the interactions between feelings, thoughts and behaviours, discussion of pros vs. cons of change.	Review decisional balance worksheet
Five (B)	<b>Module 3</b> (emotional awareness): Discussion of dominant emotions their functions, and how they are shown.	Worksheet on noticing emotions
Six (B)	<b>Module 4</b> (cognitive reappraisal): Review of common thinking traps and their influence of emotions and behaviours.	Evaluating automatic appraisals form
Seven (B)	<b>Module 5</b> (emotionally driven behaviours [EDBs]): Review of maladaptive EDBs, identification of new ones and plan for acquiring new EDBs	EDB monitoring and alternative action form
Eight (B)	<b>Module 6</b> (awareness and tolerance of physical sensations): Explanation of the rationale for mindfulness-based strategies and in-session practice.	5 minutes mindfulness exercises
Nine (B)	<b>Module 7</b> (interoceptive + situational exposure): Explanation of the habituation curve and utility of exposure, exercises used (imagine being in a hospital).	Worksheet for behavioural exposures.
Ten (B)	<b>Module 8</b> (relapse prevention): Review of progress shown and summary of past sessions.	NA

Table 2. Idiographic outcomes by phase of study

Measure	Baseline			Intervention			Nonoverlap indices			Difference
	Mean	SD	$\tau$	Mean	SD	$\tau$	PEM	PAND	NAP	$\tau^{(A-B)}$
Checking time	83.10	102.65	-.01	24.24	31.70	-0.31*	90%	81%	83%	0.67*
Checking episodes	4.00	2.59	-.10	1.67	1.24	-0.11	88%	78%	79%	-0.59*
Sleep duration	7.71	3.98	.03	9.24	2.09	-0.08	88%	64%	64%	.286
Food intake	3.38	0.92	.07	3.62	0.79	0.32*	10%	49%	56%	.122

\*denotes significance at the  $p = <0.001$


Nonoverlap indices: PEM = percentage of data exceeding the median; PAND = percentage of all nonoverlapping data; NAP = nonoverlap of all pairs.

$\tau$  indices:  $\tau$  = Kendall's tau;  $\tau^{(A-B)}$  = Kendall's Tau difference (baseline-intervention);  $\tau^U$  = Kendall's  $\tau^{(A-B)}$  with adjustment for baseline trend.

Table 3. *Nomothetic outcomes*

Measure	Time Point				Normative Data		Change Score		Measure Thresholds	
	Pre baseline	Post baseline	Mid therapy	Therapy end	Clinical M (SD)	Community M (SD)	1	2	Reliable Change	Clinical Caseness
CORE-10	24 <sup>1</sup>	20 <sup>1</sup>	12	7	19.7 (7.7)	4.7 (4.8)	8*	13*	5 (15)	Depression 13; Distress 11
Y-BOCS	28 <sup>1</sup>	24 <sup>1</sup>	17 <sup>1</sup>	15 <sup>1</sup>	24 (5.4)	7.6 (5.8)	7*	9*	6 (18)	OCD 13

*Note.* Change score 1 is the movement in scores from baseline-end to mid-therapy, change score 2 is the movement in scores from baseline to therapy end; reliable change threshold indicates the amount score change needed to meet reliable change, clinical change threshold indicates the clinical cut-off for caseness. <sup>1</sup> indicates that the score represents clinical caseness at that point in time; \* indicates reliable change has been met/exceeded. Norms obtained from Connell & Barkham, 2007 (UK norms); Frost, Steketee, Krause, & Trepanier, 1995 (US population norms); Deacon & Abramowitz, 2005 (US community norms)



Baseline median ——— OLS trend line - - - - -

Figure 1: Time series plots for idiographic measures. X-axis observations are equal to days.